Imugene's Azer-cel is a potential first-in-class allogeneic CD19...

Imugene's Azer-cel is a potential first-in-class allogeneic CD19 CAR T product candidate for patients who have relapsed following CAR T therapy. It continues to demonstrate promising results in patients with diffuse large B-cell lymphoma (DLBCL), a type of aggressive non-Hodgkin lymphoma.

At the recent J.P. Morgan Healthcare Conference presentation, Imugene signaled an update of the phase 1b trial in Q2 2024.

Although not yet confirmed, the 27th Meeting of ASGCT (American Society of Gene and Cell Therapy) to be held on the 7th May in Baltimore Maryland will most likely be the conference for the trial update.

https://annualmeeting.asgct.org/
The deadline for regular abstract submissions was the 26th January.
Notifications will be sent on the 25th March and abstracts will be released on the 8th April.

Recent discussions with the FDA suggest that Azer-cel could advance into a potential registrational study for patients already treated with autologous CAR T therapy in Q4 2024, positioning it to potentially become the first FDA-approved allogeneic CAR T therapy for blood cancers.

GLTA - Go Team Imugene
.